Here are five key points:
1. Xtant Medical’s shares closed at $3.29 on Oct. 23.
2. Brean Capital analyst Jason Wittes said Xtant Medical should grow pro-forma revenues at 12 percent.
3. The company currently has an analyst consensus of “hold.”
4. Xtant Medical had a quarterly revenue of $9.89 million, based on its June 30 report.
5. The company manufactures products for spine, orthopedic and joint surgeries.
More articles on devices:
China spinal fusion market to see double digit growth — 6 points
HSS conducts studies on a new modular partial wrist replacement: 5 takeaways
Wire stimulator technology provides chronic pain relief for San Antonio patients: 4 key points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.